Across TCGA pan-cancer cohorts, LILRB3 mass-spec protein is linked to patient survival in 4 of 34 cancer types, making it a survival-associated LILRB3 data layer compared with 22 for mass-spec protein and 5 for mutation status.

The strongest signal is observed in lung adenocarcinoma (LUAD), where higher LILRB3 mass-spec protein is associated with worse overall survival. In most high-consensus cancer types, elevated LILRB3 expression acts as an unfavorable survival marker, although some lineages such as LSCC show a favorable association.

LUAD, HNSC, and PDAC are the cancer types where LILRB3 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LUAD	OS	Quartile	All	0.669	0.953	.008	23	view →
HNSC	DFS	Median	All	0.889	1.000	.002	18	view →
PDAC	DFS	Tertile	All	0.224	0.667	.016	9	view →
LSCC	OS	Quartile	II,III,IV	0.972	0.761	.046	1	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

Exploration

Same gene, other analysis: LILRB3 tumor-vs-normal RNA expression · all LILRB3 data types